Biotechnology startup Helical has secured 10 million USD in seed funding to further the development of its virtual AI laboratory designed for pharmaceutical research and development. The round was led by Redalpine with participation from Gradient, BoxGroup, Frst, Aidan Gomez, Clement Delangue, and Mario Götze.
Founded in early 2024, Helical focuses on converting biological foundation models into reproducible in-silico workflows. The company intends to use the capital to deepen its deployments across various therapeutic areas with current clients and expand its engagement with additional pharmaceutical organizations. Furthermore, the funding will support the enhancement of the platform's evidence layer to improve predictive performance across different disease areas.
Founded in early 2024, Helical focuses on converting biological foundation models into reproducible in-silico workflows. The company intends to use the capital to deepen its deployments across various therapeutic areas with current clients and expand its engagement with additional pharmaceutical organizations. Furthermore, the funding will support the enhancement of the platform's evidence layer to improve predictive performance across different disease areas.